Search Results for:

HUYABIO Announces HBI-8000 Brand Name of Hiyasta™

HUYABIO Announces HBI-8000 Brand Name of Hiyasta™

San Diego, CA, USA – June 24, 2021 – HUYABIO International (HUYABIO™), the leader in accelerating   global development of China’s pharmaceutical innovations, announced today that HBI-8000 will be marketed under the brand name Hiyasta™ in Japan. Hiyasta was recently approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of adult T-cell leukemia/lymphoma (ATLL) as monotherapy.

HUYABIO International Receives Regulatory Approval for HBI-8000 Monotherapy of Adult T-cell Leukemia/Lymphoma in Japan

HUYABIO International Receives Regulatory Approval for HBI-8000 Monotherapy of Adult T-cell Leukemia/Lymphoma in Japan

HUYABIO’s partner Meiji Seika to market the drug in Japan

San Diego, CA, USA – June 23, 2021 – HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the regulatory approval for HBI-8000 monotherapy of relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATL) by the Japanese Pharmaceuticals and Medical Devices Agency.

Jay W. Mason, MD

Jay W. Mason, MD

 Dr. Mason has served as a Cardiology consultant to HUYABIO since 2017. He is Professor of Medicine (Cardiology) at the University of Utah, Chief Medical Officer at Spaulding Clinical Research, and an independent consultant in cardiac safety. He obtained his undergraduate degree at Princeton University and his MD degree at the University of Pennsylvania.